Get the latest tech news

GLP-1 pills are coming, and they could revolutionize weight-loss treatment

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing.

The Danish drugmaker reported last year that a late-stage study in people who don’t have diabetes showed that the daily pill led to an average weight loss of 15% over 68 weeks, a similar result as seen in trials of Wegovy. Lilly, which also makes Zepbound and Mounjaro, reported last year that a midstage trial found that people taking orforglipron for 36 weeks lost an average of 15% of their body weight – about the same amount as oral semaglutide in less time. Novo Nordisk also agreed to spend up to $1.1 billion last year to acquire Inversago Pharma, gaining an experimental oral drug called monlunabant that’s designed to block a cannabinoid receptor important in regulating appetite.

Get the Android app